

Review

Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis[†]

Rebecca Strawbridge, Ben Carter, Lindsey Marwood, Borwin Bandelow, Dimosthenis Tsapekos, Viktoriya L. Nikolova, Rachael Taylor, Tim Mantingh, Valeria de Angel, Fiona Patrick, Anthony J. Cleare and Allan H. Young

Background

Depression is considered to have the highest disability burden of all conditions. Although treatment-resistant depression (TRD) is a key contributor to that burden, there is little understanding of the best treatment approaches for it and specifically the effectiveness of available augmentation approaches.

Aims

We conducted a systematic review and meta-analysis to search and quantify the evidence of psychological and pharmacological augmentation interventions for TRD.

Method

Participants with TRD (defined as insufficient response to at least two antidepressants) were randomised to at least one augmentation treatment in the trial. Pre-post analysis assessed treatment effectiveness, providing an effect size (ES) independent of comparator interventions.

Results

Of 28 trials, 3 investigated psychological treatments and 25 examined pharmacological interventions. Pre-post analyses demonstrated *N*-methyl-*D*-aspartate-targeting drugs to have the highest ES (ES = 1.48, 95% CI 1.25–1.71). Other than aripiprazole (four studies, ES = 1.33, 95% CI 1.23–1.44) and lithium (three studies, ES = 1.00, 95% CI 0.81–1.20), treatments were each investigated in less than three studies. Overall, pharmacological (ES = 1.19, 95% CI 1.08–1.30) and psychological (ES = 1.43, 95% CI 0.50–2.36) therapies yielded higher ESs than pill placebo (ES =

0.78, 95% CI 0.66–0.91) and psychological control (ES = 0.94, 95% CI 0.36–1.52).

Conclusions

Despite being used widely in clinical practice, the evidence for augmentation treatments in TRD is sparse. Although pre-post meta-analyses are limited by the absence of direct comparison, this work finds promising evidence across treatment modalities.

Declaration of interest

In the past 3 years, A.H.Y. received honoraria for speaking from AstraZeneca, Lundbeck, Eli Lilly and Sunovion; honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion and Janssen; and research grant support from Janssen. In the past 3 years, A.J.C. received honoraria for speaking from AstraZeneca and Lundbeck; honoraria for consulting with Allergan, Janssen, Livanova, Lundbeck and Sandoz; support for conference attendance from Janssen; and research grant support from Lundbeck. B.B. has recently been (soon to be) on the speakers/advisory board for Hexal, Lilly, Lundbeck, Mundipharma, Pfizer, and Servier. No other conflicts of interest.

Keywords

Treatment-resistant depression; augmentation; psychological therapy; psychopharmacology; systematic review.

Copyright and usage

© The Royal College of Psychiatrists 2018.

The burden of treatment-resistant depression (TRD) is challenging to quantify. It has eluded a universal definition¹ but is prevalent and encompasses considerably greater severity, chronicity, recurrence, admission to hospital and comorbidity with both psychiatric and non-psychiatric disorders than non-resistant major depressive disorder (MDD).² Despite this, TRD has been a neglected area of research with numerous reviews calling for more comprehensive evidence. Indeed, many of these reviews have considered people as treatment resistant if they have failed one previous treatment trial (in contrast with the most popular guidelines¹), in part because this represents the inclusion criteria frequently used in clinical trials. One such example examined the pharmacological augmentation treatments that the majority of TRD patients are treated with in practice.³ Only when using the less-stringent criteria of TRD was there sufficient evidence for a network meta-analysis in 2015,³ and the authors reported significant efficacy of quetiapine, aripiprazole, lithium and thyroid hormone compared with placebo. However, this evidence may not apply to people with more severe TRD. Pre-post analyses have the

benefit of not requiring a placebo arm and the ability to compare effectiveness estimates between heterogeneous treatment approaches.⁴ Additionally, pre-post effect sizes (ESs) provide good clinical face validity as an estimate of the magnitude of effects seen with treatment in practice, incorporating both those specific to the individual modality as well as non-specific effects and the passage of time.⁴

Objectives

This review aimed to qualify and quantify the evidence of augmentation treatments for TRD by using the most common clinical definition (i.e. two or more failed treatments in current episode) and to compare ESs across psychological and pharmacological interventions. To our knowledge, this is the first meta-analysis comparing pre-post treatment effects for all augmentation therapies across the two most popular treatment classes for depression in clinical practice. Specifically, our objectives were to:

- determine the efficacy of adjunctive interventions for TRD through comparisons between treatment category (i.e. pharmacological or psychological), class (e.g. antipsychotics, mood stabilisers) and individual treatments;

[†] The original version of this article was published with incorrect results in the abstract. A notice detailing this has been published and the errors rectified in the online PDF and HTML versions, and also in the printed issue.

- (b) provide an indication of the acceptability and tolerability of these treatments.

Methods

Criteria for considering studies for the review

The protocol for this systematic review was published via PROSPERO (registration code CRD42018088009),⁵ where full details of the search are available and reported consistently following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines.

Types of included studies

Only randomised controlled trials (RCTs) of at least 10 participants and at least one suitable augmentation treatment were included.

Types of participants

Participants must have been adults with TRD, defined as unremitted depression despite at least two courses of treatment of adequate dose and duration undertaken in the current episode (current best-practice guidelines⁶). Both within-class (in addition to between-class) switching of antidepressants and psychological treatments were permitted as they are considered valid contributors to a TRD definition.¹ Studies including patients with psychotic or bipolar depression were excluded because of clear treatment distinctions.

Types of interventions

Participants must have been taking at least one continuation treatment prior to randomisation to a new (augmentation) intervention. The same eligibility criteria were employed for both continuation and augmentation treatments: permitted pharmacological treatments were any included in the Maudsley Treatment Inventory¹ and psychological treatments from the National Institute for Health and Clinical Excellence depression guidelines⁷ or those with multiple meta-analyses supporting use in depression. Eligible comparator treatments included pill placebo, another pharmacological agent, another psychological intervention, waiting list, active control or treatment as usual (TAU).

Types of outcome measures

Primary outcome: The primary outcome was clinical improvement (ES) between pre- and post-treatment time points for each eligible treatment/comparator arm. One efficacy measurement was selected, prioritising validated, clinician-rated measures of depression severity (and if not available, a patient-rated depression scale or assessment of global improvement if no depression symptom scale was reported).

Secondary outcomes: A measure of adherence (e.g. trial dropout due to any cause or treatment adherence data) and a measure of tolerability (e.g. adverse event or side-effects data) were recorded where available.

Search methods for identification of studies

MEDLINE and Institute for Scientific Information (ISI) Web of Science were searched in addition to citation lists from notable papers, available reviews and included articles. The following medical subject headings or text word terms were used for the electronic database search (all fields): (depress* OR MDD OR major depress*) AND (resistan* OR refractor* OR non-respon* OR non-respon* OR un-respon* OR unrespon* OR TRD OR fail* OR inadequate OR difficult OR intractable) AND (augment* OR adjunct*

OR add-on OR combin* OR co-administ*) AND (randomi* OR RCT) AND (treatment OR intervention OR trial). No language restriction was made.

Data collection and analyses

Article review and data extraction

All search results were evaluated against inclusion criteria independently by pairs of review authors (R.S., L.M., R.T., T.M., V.d.A., D.T., V.L.N. and F.P.), with disparities addressed by consensus with additional review authors (A.H.Y., A.J.C., B.C.). Following inclusion, data extraction was conducted by authors as above.

Quality assessment

The methodological quality assessment was examined using the Scottish Intercollegiate Guidelines Network⁸ and the Cochrane Risk of Bias (RoB)⁹ tools. Studies were assessed by two reviewers (rated as RoB high, low or unclear) for nine domains: sequence generation, allocation concealment, blinding of outcome assessors, use of intention-to-treat analysis, comparability of randomised groups at baseline, inter-site differences in findings, the potential for selective outcome reporting and presence of for-profit bias (allegiance). Using individual criterion ratings, each study was given an overall RoB rating of low, moderate or high (see Supplementary Table 1 available at <https://doi.org/10.1192/bjp.2018.233>).

Measures of treatment effect

Continuous data describing treatment effectiveness were extracted (e.g. pre- and post-severity scores or longitudinal change in severity scores) and presented as a standardised mean difference (Hedges' *g* ES). Using a random-effects model, meta-analyses computed a pooled ES with 95% confidence intervals (CIs), *P*-values and the *I*² statistic. Statistical heterogeneity was considered important if *I*² exceeded 60%⁹ and explored using subgroups. The following comparisons were planned to assess the primary outcome:

- pooled effects of augmentation intervention/comparator categories (i.e. psychological treatment, psychological comparator, pharmacological treatment and pharmacological comparator);
- pooled effects of augmenters by class (e.g. selective serotonin reuptake inhibitor, serotonin–noradrenaline reuptake inhibitor, antipsychotic, mood stabiliser);
- pooled effects of individual treatment interventions within above categories.

Additional comparisons

The following secondary outcomes were quantitatively or qualitatively explored: acceptability, tolerability and an exploration of pairwise active-control comparisons to provide an indicated effect of treatment versus comparator trial arm, validating findings against the current gold standard.¹⁰

Subgroups used to explore heterogeneity

Planned subgroups used to explore statistical heterogeneity included study quality (RoB) and trial duration, as well as participant treatment-resistance definition, continuation treatments, comorbidities, depression severity, duration of episode and treatment setting.

Changes made since protocol registration

The permitted range of treatment duration was amended from a range of 6–26 weeks to include any duration where expectations




Fig. 1 Study flow diagram showing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. *A further 11 articles were included in the systematic review as they contained additional information but were pooled analyses or subgroup analyses. ISI, Institute for Scientific Information; TRD, treatment-resistant depression.

of clinical efficacy were reported. This was to account for the variable windows of clinical efficacy between different treatment mechanisms (e.g. ketamine, which has well-documented rapid antidepressant effects). Excluding ketamine, the Maudsley Treatment Inventory recommends durations of 6 weeks for full clinical effect;¹ therefore we selected to subgroup included trials of less than 6 weeks as ‘short-term’ (this excludes rapid-onset treatments such as ketamine)¹ and those more than 26 weeks as ‘long-term’ treatment durations.

Results

Systematic search results

After duplicates were removed, 2246 manuscripts from the MEDLINE and ISI Web of Science databases (all years to 6 February 2018) and hand searches were screened. Of 297 full texts reviewed, 39 articles describing 28 studies were eligible for inclusion. A PRISMA flow chart presents a breakdown of the search process (Fig. 1).

Characteristics of included studies

Within the 28 included RCTs, 5461 TRD participants were randomised. All analysed interventions were of parallel-group studies, with ten trials (36%) conducted in North America, seven (25%) in Europe, six (21%) in Asia, four (14%) across multiple continents

and one (4%) in South America. The mean study size was 199 (s.d. = 270, range 20–1293). The duration of interventions ranged from 5 days (ketamine¹¹) to 18 months (long-term psychoanalytic psychotherapy¹²), with a median duration of 6 weeks (interquartile range = 2).

Characteristics of participants

Participants had a median age of 45 years (interquartile range = 4) and 66% were female. All analysed individuals had unremitted depression despite at least two adequate treatment trials in the current episode. A total of 15 studies defined TRD fully retrospectively (using a minimum duration of previous treatments of 4 or 6 weeks), whereas 12 required at least one unsuccessful treatment retrospectively and one prospectively. One study undertook two treatment trials to determine treatment resistance fully prospectively.¹³ Most studies did not consider psychological treatments to contribute to TRD definition; only Fonagy *et al*¹² required one pharmacological and one psychological treatment failure as a minimum TRD criterion for study entry. Table 1 contains further details.

Quality assessment

Supplementary Table 1 contains the RoB ratings across criteria and studies. A total of 12 studies were rated as having a low RoB,^{2,11,4–23} 12 had a moderate RoB^{24–35} and 4 had a high RoB.^{13,36–38} The most

Table 1 Details of all studies included in this review

Reference	Intervention	Continent of trial	TRD definition used (number of unsuccessful treatments)	Setting	Comorbidity	Continuation treatment(s)	Continuation therapy
Mood stabilisers Nierenberg <i>et al</i> ²⁰	Lithium/placebo	North America	1+ adequate ADM (retrospective), plus 6 weeks prospective ADM	OP	Some	NOR	Mono
Girlanda <i>et al</i> ¹⁵	Lithium/TAU	Europe	2+ adequate ADM	OP	Frequent psychiatric	TAU	Mono/Poly
Schindler <i>et al</i> ³⁸	Lithium/lamotrigine	Europe	2+ ADM >6 weeks	IP	Some	NR	Mono
Barbee <i>et al</i> ²⁷	Lamotrigine/placebo	North America	1+ ADM >6 weeks (retrospective), plus 8 weeks prospective ADM	NR	None prominent	PAR	Mono
Santos <i>et al</i> ²¹	Lamotrigine/placebo	South America	2+ adequate ADM	OP	Some	Any ADM	Mono
Antipsychotics Berman <i>et al</i> ²⁹	Aripiprazole/placebo	North America	1+ ADM >6 weeks (retrospective), plus 8 weeks prospective ADM	OP	None prominent	ESC, FLU, PAR, SER, VEN	Mono
Berman <i>et al</i> ³⁰	Aripiprazole/placebo	North America	1+ ADM >6 weeks (retrospective), plus 8 weeks prospective ADM	OP	None prominent	ESC, FLU, PAR, SER, VEN	Mono
Marcus <i>et al</i> ³²	Aripiprazole/placebo	North America	1+ ADM >6 weeks (retrospective), plus 8 weeks prospective ADM	OP	NR	ESC, FLU, PAR, VEN	Mono
Ozaki <i>et al</i> ³⁴	Aripiprazole/placebo	Asia	1+ ADM >6 weeks (retrospective), plus 8 weeks prospective ADM ^h	OP and IP	None prominent	PAR, FLUV, SER, MIL, DUL	Mono
Thase <i>et al</i> ²²	Brexpiprazole/placebo	North America/ Europe	1+ ADM (retrospective), plus 1 prospective ADM	OP	None prominent	ESC, FLU, PAR, SER, DUL, VEN	Mono
Thase <i>et al</i> ²³	Brexpiprazole/placebo	North America/ Europe	1+ ADM (retrospective), plus 1 prospective ADM	OP	None prominent	ESC, FLU, PAR, SER, DUL, VEN	Mono
Shelton <i>et al</i> ³⁵	Olanzapine/placebo	North America	2+ ADM >4 weeks (retrospective), plus 6 weeks prospective ADM	OP	None prominent	FLU	Mono
Dunner <i>et al</i> ²⁶	Ziprasidone	North America	1+ ADM >4 weeks (retrospective), plus 6 weeks prospective ADM	OP	None prominent	SER	Mono
Psychological therapies Eisendrath <i>et al</i> ¹⁸	MBCT/HEP	North America	2+ ADM >4 weeks	OP	Some	TAU (ADM)	Poly
Fonagy <i>et al</i> ¹²	LTPP/TAU	Europe	2+ treatments (≥1 ADM, ≥1 psychological)	OP	Some	TAU	Mono/Poly
Hauksson <i>et al</i> ²⁵	CBT/TAU	Europe	2+ adequate ADM	IP	Frequent psychiatric	Multimodal rehabilitation	Mono/Poly
NMDA targets Heresco-Levy <i>et al</i> ¹⁶	D-cycloserine/placebo	Asia	2+ adequate ADM	OP	None prominent	TAU (ADM)	Mono/Poly
Husain <i>et al</i> ¹⁷	Minocycline/placebo	Asia	2+ adequate ADM	OP	None prominent	TAU	Mono/Poly
Su <i>et al</i> ¹¹	Ketamine/placebo	Asia	2+ adequate ADM	OP	Frequent psychiatric	NR	NR
Other pharmacological Moller <i>et al</i> ³³	Dexmecamylamine/placebo	All except Oceania	1+ ADM >6 weeks (retrospective), plus 8 weeks ADM prospective	OP	None prominent	ESC, CIT, FLU, PAR, SER, DUL, VEN	Mono
Multiple treatment classes Bauer <i>et al</i> ²⁸	Quetiapine/lithium	Europe	2+ ADM (retrospective) ^a	OP and IP	None prominent	Any ADM	Mono
Fang <i>et al</i> ¹⁹	Risperidone/sodium valproate/buspiron/ trazodone/thyroid hormone	Asia	2+ adequate ADM (stage 2, Thase and Rush criteria)	OP and IP	Some	PAR	Mono

(Continued)

Table 1 (Continued)

Reference	Intervention	Continent of trial	TRD definition used (number of unsuccessful treatments)	Setting	Comorbidity	Continuation treatment(s)	Continuation therapy
Nierenberg <i>et al</i> ¹⁶	Lithium/thyroid hormone	North America	2+ ADM (from stages 1 to 3 STAR*D study)	OP	Frequent psychiatric	BUP, SER, VEN, CIT	Mono
Short-term treatments Baumann <i>et al</i> ²⁴	Lithium/placebo	Europe	1+ ADM (retrospective), plus 4 weeks prospective ADM	IP	Some	CIT	Mono
McAllister-Williams <i>et al</i> ¹⁴	Metyrapone/placebo	Europe	2+ ADM >6 weeks (Massachusetts General Hospital staging criteria)	OP	None prominent	TAU; serotonergic ADM	Mono/Poly
Yoshimura <i>et al</i> ¹³	Aripiprazole	Asia	2+ ADM 4 weeks (prospective)	NR	None prominent	PAR, SER	Mono
Parkar <i>et al</i> ¹⁷	Methylphenidate/placebo	North America, Asia	2+ ADM >6 weeks ^a	OP	None prominent	Most ADM	Mono
Maes <i>et al</i> ¹¹	Pindolol/fluoxetine/placebo	North America	2+ ADM >4 weeks (stages 2–5, Thase and Rush criteria) ^a	IP	Some (physical)	Trazodone	Mono

TRD, treatment-resistant depression; ADM, antidepressant medication; OP, out-patient; NR, not reported; PAR, paroxetine; ESC, escitalopram; FLU, fluoxetine; SER, sertraline; VEN, venlafaxine; FLU, fluvoxamine; MIL, milnacipran; DUL, duloxetine; MBC1, mindfulness-based cognitive therapy; HEP, health education programme; LTPP, long-term psychoanalytic psychotherapy; CBT, cognitive-behavioural therapy; CIT, citalopram; STAR*D, Sequenced Treatment Alternatives to Relieve Depression; BUP, bupropion.
a. Describes eligible TRD subgroup where full sample did not meet review inclusion criteria.

common individual criteria rated as high RoB were being funded and/or conducted by an industrial sponsor (12 trials) and not applying or reporting an intention-to-treat analysis (seven trials). Blinding was not always maintained but was often maximised where possible, i.e. in the ketamine trial (reportedly double-blind¹¹), psychological trials (two out of three trials report blinding of outcome assessors^{12,18}) and open-label studies (all but one³⁸ reporting blinded outcome raters).

Effectiveness of augmentation treatment

There was clinical diversity in the design (see Table 1); intervention and outcomes were reported (see Supplementary Table 2) across studies.

Primary outcomes

Pre-post meta-analyses indicated improvements in depression with all interventions examined ($P < 0.001$). From 23 studies including 3246 participants, pharmacological treatments yielded an overall ES of 1.15 (95% CI 1.01–1.29, $I^2 = 82.7$). Psychological therapies as a category comprised 3 studies totalling 276 participants, showing similar effects (ES = 1.43, 95% CI 0.50–2.36, $I^2 = 95.3$). For the majority of initial analyses conducted, severe heterogeneity limited the interpretability of comparisons (see Supplementary Table 3). The three studies with a high RoB contributed substantially to this heterogeneity, demonstrating either low³⁶ or high^{13,38} outlier ESs and the subgroup of active treatments trialled for a short-term duration (lithium,²⁴ metyrapone¹⁴) showed an ES of 0.61 (95% CI 0.37–0.85, $I^2 = 0$); their removal from meta-analyses notably reduced heterogeneity. In contrast, long-term treatment trials of lithium¹⁵ and psychoanalytic psychotherapy¹² were homogeneous (ES = 0.67, 95% CI 0.44–0.90, $I^2 = 4.6$) and did not affect heterogeneity of main analyses so were not excluded. Effects of all placebo trials (pill ES = 0.78, psychological ES = 0.94) exhibited findings similar to the sub-therapeutic-duration pharmacological studies (ES = 0.61) and were consistently lower than active treatments; see Fig. 2 and Table 2. All active treatment effects are displayed in Supplementary Fig. 1 and control arms in Supplementary Fig. 2.

Pharmacological treatment classes

Pharmacological interventions without high RoB and trialled for a therapeutic duration had an ES of 1.19 (95% CI 1.08–1.30, $I^2 = 64.6$).

N-methyl-D-aspartate (NMDA)-targeting drugs showed the most consistent and large ES of the pharmacological classes (ES = 1.48, 95% CI 1.25–1.71, $I^2 = 0$), despite the individual agents having different mechanisms of action.

Mood stabilisers demonstrated an overall ES of 1.12 (95% CI 0.92–1.31, $I^2 = 23.6$), exhibiting low heterogeneity only. Lithium was the most frequently investigated mood stabiliser and had a slightly smaller ES than the overall class without heterogeneity (three studies; ES = 1.00, 95% CI 0.81–1.20, $I^2 = 0$).

Antipsychotics also had an ES of 1.12 (95% CI 0.98–1.26, $I^2 = 75.0$) and exhibited heterogeneity, likely due to differences between treatments within this class. Aripiprazole was the most frequently assessed antipsychotic and provided a consistent effect across four studies (ES = 1.33, 95% CI 1.23–1.44, $I^2 = 0$).

Medications not falling into the above mechanisms were grouped together (trazodone, buspirone, thyroid hormone and dexmecamylamine) and showed an ES of 1.36 (95% CI 1.09–1.63, $I^2 = 46.4$), comparable in terms of heterogeneity and ES to the other pharmacological treatments.




Fig. 2 Treatment effects by class. Augmentation treatments for treatment-resistant depression, pre-post effect size (Hedges' *g*) and 95% confidence intervals (see Supplementary Table 3 for values) are shown. *Pharmacological treatments categorised with mechanisms not akin to *N*-methyl-*D*-aspartate (NMDA) agents, mood stabilisers or antipsychotics: this comprised trazodone (serotonin antagonist and reuptake inhibitor), buspirone (anxiolytic), dexmecamylamine (nicotinic channel modulator) or thyroid hormone. *k*, number of studies; ES, effect size.

Table 2 Results of meta-analyses assessing primary outcome

Outcome	Intervention	<i>k</i>	<i>n</i>	ES	s.e.	95% CI	Heterogeneity (<i>I</i> ²)
Pharmacological		23	2965	1.19	0.05	1.08–1.30	64.6
Mood stabilisers	All	6	260	1.12	0.10	0.92–1.31	23.6
	Lithium	3	157	1.00	0.10	0.81–1.20	0.0
	Lamotrigine	2	64	1.13	0.17	0.79–1.47	0.0
	Sodium valproate	1	39	1.64	0.25	1.16–2.12	n/a
Antipsychotics	All	10	1503	1.12	0.07	0.98–1.26	75.0
	Aripiprazole	4	655	1.33	0.05	1.23–1.44	0.0
	Brexpiprazole	2	638	0.96	0.06	0.85–1.06	17.3
	Ziprasidone	1	41	0.65	0.17	0.31–0.99	n/a
	Risperidone	1	45	1.15	0.19	0.77–1.53	n/a
	Quetiapine	1	114	1.05	0.12	0.82–1.28	n/a
	Olanzapine	1	10	0.98	0.38	0.22–1.73	n/a
NMDA targets	All	3	81	1.48	0.12	1.25–1.71	0.0
	Ketamine	1	47	1.47	0.13	1.22–1.72	n/a
	<i>D</i> -cycloserine	1	13	1.47	0.46	0.57–2.36	n/a
	Minocycline	1	21	1.54	0.29	0.97–2.11	n/a
Other mechanisms	All	4	1121	1.36	0.14	1.09–1.63	46.4
SARI	Trazodone	1	47	1.67	0.23	1.23–2.12	n/a
Anxiolytic	Buspirone	1	46	1.57	0.22	1.14–2.00	n/a
Thyroid	Thyroid hormone	1	48	1.15	0.19	0.79–1.52	n/a
Nicotinic	Dexmecamylamine	1	980	1.13	0.18	0.78–1.49	n/a
Pill placebo ^a		16	1552	0.78	0.07	0.66–0.91	68.8
Psychological therapies	All	3	276	1.43	0.23	0.50–2.36	95.3
	MBCT	1	67	0.99	0.21	0.58–2.41	n/a
	LTPP	1	67	0.59	0.13	0.33–0.85	n/a
	CBT	1	142	1.74	0.20	1.35–2.13	n/a
Psychological comparators	All	3	162	0.94	0.30	0.36–1.52	89.1
	TAU	2	98	0.77	0.37	0.06–1.49	88.0
	Active placebo	1	64	1.27	0.17	0.94–1.59	n/a
Short-term treatments (excluded from main analyses)	All	2	79	0.61	0.12	0.37–0.85	0.0
	Lithium	1	10	0.36	0.12	0.13–0.59	n/a
	Metyrapone	1	69	0.63	0.13	0.37–0.89	n/a

Results of meta-analyses assessing treatment effectiveness at a category, class and individual intervention level for studies with data available for meta-analyses without a high risk of bias accounting for therapeutic duration of interventions trialled (for results including high risk of bias and short-term durations, see Supplementary Table 3). Bold text indicates pooled effects of each treatment category. *k*, number of studies; *n*, number of participants; ES, effect size (Hedges' *g*); n/a, not applicable; NMDA, *N*-methyl-*D*-aspartate; SARI, serotonin antagonist and reuptake inhibitor; MBCT, mindfulness-based cognitive therapy; LTPP, long-term psychoanalytic psychotherapy; CBT, cognitive-behavioural therapy; TAU, treatment as usual. a. Pill placebo, without the two short-term studies whose active treatments had been excluded from their respective analyses, was as effective without these two studies (ES = 0.82, 95% CI 0.69–0.95) and as heterogeneous (*I*² = 68.3).

Psychological treatment classes

The overall ES of psychological therapies (three studies; ES = 1.43, 95% CI 0.50–2.36) contained substantial heterogeneity (*I*² = 95.3),

likely due to different therapeutic modalities that we were not able to subgroup further due to lack of studies. Within this analysis, cognitive-behavioural therapy (CBT) had the highest ES of all

individual treatments (one study;²⁵ ES = 1.74), whereas psychoanalytic psychotherapy had the smallest (one study;¹² ES = 0.59).

Publication bias was not apparent (detail available from the author on request).

Secondary outcomes

Active versus control (pairwise) meta-analyses

Only three treatment classes were examinable due to data availability. Despite heterogeneity of therapies and studies, they proposed that psychological treatments were more beneficial than usual care or an active control (three studies; ES = 0.45, 95% CI 0.09–0.81, $I^2 = 63.8$). Antipsychotics showed effectiveness when compared to placebo (seven studies; ES = 0.38, 95% CI 0.18–0.58, $I^2 = 59.4$). The number of mood-stabiliser studies was lower in the pairwise comparison than in pre-post analyses due to a paucity of placebo-controlled trials, and they were not significantly more effective than placebo (four studies; ES = 0.13, 95% CI –0.14 to 0.39, $P = 0.34$, $I^2 = 0$).

Tolerability and acceptability

Tolerability and acceptability were defined differently between studies and were not sufficiently homogeneous to consider quantitatively in meta-analyses.

Eight studies reported the total number of adverse events occurring in each arm; they were higher in active versus placebo arms for most interventions but equal between active and placebo arms in the D-cycloserine¹⁶ and minocycline¹⁷ trials. This rate might be heavily influenced by a large number of adverse events occurring in a minority of patients, and of seven studies reporting the percentage of participants experiencing at least one adverse event, most were similar between treatment arms.

The highest dropout rate was in the ziprasidone intervention (41% in the lower-dose arm).²⁶ There was a discrepancy of more than 10% in participant dropout between arms in this study, as well as in the studies by Heresco-Levy *et al*¹⁶ (D-cycloserine 23% versus placebo 11%) and Husain *et al*¹⁷ (minocycline 24% versus 10% placebo). No dropouts were reported in the CBT trial arms of TAU and individual CBT (two participants withdrew from group CBT)²⁵ or from the 1-week lithium placebo-controlled study (either trial arm).²⁴

Discussion

Meta-analytic estimates of treatment effects for resistant and non-resistant depression

In contrast to TRD, progress is evolving regarding the comparative effectiveness of common treatments for MDD, as exemplified by a recent, extensive network meta-analysis: Cipriani *et al*³⁹ identified over 500 double-blind randomised trials of antidepressant monotherapy for MDD (in contrast to the 28 that we found for TRD augmentation) and found all to be significantly more effective than placebo. Another meta-analysis of pharmacological augmentation treatments for depression non-responsive to one or more antidepressant reported comparable ESs.³ We anticipate smaller ESs within TRD populations. The greatest pre-post effect of augmentation that we report is for medications targeting the NMDA receptor, i.e. ketamine (antagonist), D-cycloserine (partial agonist) and minocycline (antagonist). This finding supports increasing attention towards drugs acting on this pathway, as illustrated by a network meta-analysis of pharmacological and somatic treatments for non-responsive depression reporting ketamine to have the strongest short-term efficacy of treatments studied.⁴⁰ It is notable, however,

that this finding was based on three studies only; population or design differences between studies may have yielded stronger effects in these trials than if directly compared with other interventions. Ketamine produced the highest ES of the NMDA medications but it is particularly challenging to maintain interviewer blinding with this treatment, although Su *et al*¹¹ reported the trial as double blind. Based on a larger number of studies, our findings also indicate that for individuals with a history of two unsuccessful treatments in the current episode, aripiprazole is effective, but it is important to note that all trials investigating aripiprazole had a potential allegiance effect. The evidence is less certain (often assessed in open-label designs^{15,28,38}) but promising for lithium. The World Federation of Societies of Biological Psychiatry Task Force recommends lithium as the first-line augmentation option for TRD, and quetiapine or aripiprazole as alternatives;⁴¹ however, we identified only one randomised quetiapine trial in the current review (found to be non-inferior to lithium). As such, it is clear that much more work in this field is required.

Effects of interventions versus placebo in randomised studies for TRD

Even a pill placebo response is variable under some methodological conditions, suggesting that there is some small scope for improvement for individuals with TRD without augmenting with a new active treatment. The ES and confidence intervals for placebo were heterogeneous across studies (as displayed in Supplementary Fig. 2), demonstrating that indeed there are limitations to inferring the relative effects of interventions across diverse investigations. Placebo and active-treatment outcomes will have been influenced by a multitude of factors which differed across trials (including but not limited to the maintenance of blinding, analyses undertaken, inclusion criteria relating to comorbidities, severity, etc.). Notwithstanding, it does appear that both psychological and pharmacological treatments are more effective than either pill or psychological controls alone, even for already resistant people. Specifically, the treatment classes whose pre-post confidence interval did not overlap with the pill-placebo estimates were mood stabilisers, antipsychotics, NMDA drugs and medications with 'other' mechanisms. This was not the case for psychological treatments which contained a wide confidence interval or for short-term treatment durations.

Effectiveness of psychological versus pharmacological intervention

For MDD, psychological therapies demonstrate overall comparable ESs to pharmacological interventions, according to a meta-analysis of direct comparisons.⁴² The most recent review investigating psychological treatments for TRD identified only two randomised studies, both underpowered and defining TRD loosely; one had found comparable benefits of CBT and antidepressants, whereas the other reported clinical benefits of CBT but not antidepressants.⁴³ The importance of building the psychological evidence base is clear and we predict that over the next decade growing efforts in this field will reduce the current uncertainty of their effectiveness for this population.⁴⁴

Many psychological trials were excluded from the current review as they focused on chronicity or recurrence of depression rather than on the number of failed treatments. This limitation reflects the lack of integration between psychological and pharmacological fields and the difficulty in operationalising a measure of treatment response, particularly for past psychological therapies (including treatment adequacy, adherence, dose, duration, intensity and other factors likely to influence outcome). The CoBaIT RCT has been seminal in the field, finding CBT adjunct to usual care as clinically effective (odds ratio of 3.26),⁴⁵ but was not eligible for

inclusion in the current review due to only requiring non-response to 6 weeks of one ongoing antidepressant. It is important to note that for most people with TRD, a combination of pharmacological and psychological approaches may be the most effective treatment both in terms of acute response and relapse prevention,⁴⁶ although only pharmacological continuation treatments were focused on in the original studies included in this review.

Limitations and strengths

This work highlights the weakness of the evidence base for augmentation treatments for TRD. Inconsistency of TRD definition excluded a large number of studies, and mediating and moderating factors (such as TRD or baseline severity, continuation treatments and case mix of included patients) limited the ability to control confounders. However, 23 studies comprising a total of 5034 participants exhibited consistency of findings. Limited comparable data were available on the tolerability and acceptability alongside effectiveness and we were not able to consider the influence of patient/investigator blinding, intention-to-treat analyses or allegiance effects in meta-analyses. These factors may have influenced ESs, although they have not notably affected similar results in other reviews.^{4,39} Due to the limited number of psychological studies included, uncertainty remains over the benefit of CBT, psychoanalytic therapy and mindfulness-based cognitive therapy in this population.

Meta-analytic comparisons between treatment types have been deemed unsuitable (unless compared directly in original studies), but pre-post meta-analysis provides indications of effectiveness that can be compared between modalities. The pre-post analysis approach may show larger ESs due to spontaneous or natural remission or patient expectations of effectiveness,¹⁰ but the likelihood of this is attenuated in TRD populations who have experienced non-effective treatments and have a lower natural recovery rate than MDD as a whole. These also therefore reflect effects as seen in real-world clinical practice. Pre-post analysis has the advantage of permitting comparisons between different treatment types and controls, which is not suitable for traditional meta-analysis (e.g. drug placebo pills have a larger effect than a waiting-list control,⁴ although no waiting-list controls were examined in the present studies). In spite of these advantages it must be highlighted that indirectly comparing ESs between treatments in this way does not account for between-study variability (including but not limited to sociodemographic and clinical differences between recruited participants, the adequacy and delivery of treatment, and other procedural and analytic distinctions).

Clinical implications

There has been continued controversy surrounding the comparison of psychological and medication-based treatment for depression. We have not found strong evidence that either method is more effective in TRD specifically, although we highlight an urgent need for more intensive investigation of psychological therapy programmes. This study also illustrates that a short duration of treatment affects outcomes more than differences between treatment modalities. However, our results indicate that both psychological and pharmacological treatments are more effective than either pill or psychological control, even for already resistant people. Far from being 'lost causes', our findings demonstrate that more therapeutic work is needed to achieve an optimal response for this sub-population. Specifically, clinicians should not rule out CBT if it is being delivered with sufficient intensity and by skilled therapists.²⁵ Our findings also confirm previous work indicating that aripiprazole and – to a lesser extent – lithium are effective treatments, supporting their current recommendation as first-line therapies.³¹

Although the measured ESs with these two pharmacotherapies are similar to other options, the fact that they have been more thoroughly investigated in a larger number of studies underlines their status as first-choice options. Although unconfirmed, even if some medication-based treatments are shown to have greater efficacy overall in TRD, treatment decisions should necessarily remain a clinical judgement. Clinicians need to balance difficulties with tolerability of medications in addition to the durability of effects and, vitally, patient preference when deciding on the most appropriate treatments to use.

Rebecca Strawbridge, BSc, MSc, PhD, Post-Doctoral Research Associate, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; **Ben Carter**, BSc, MSc, PhD, Senior Lecturer in Biostatistics, Department of Biostatistics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; **Lindsey Marwood**, BSc, MSc, PhD, Post-Doctoral Trial Manager, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; **Borwin Bandelow**, MD, PhD, Professor of Psychiatry and Neurology, Department of Psychiatry and Psychotherapy, University Medical Centre, Göttingen, Germany; **Dimosthenis Tsapekos**, BSc, MSc, PhD Student, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; **Viktoria L. Nikolova**, BSc, MRes, Research Assistant, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; **Rachael Taylor**, BA, MSc, PhD Student, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; **Tim Mantingh**, BSc, MSc, Research Assistant, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London and South London and Maudsley National Health Service Foundation Trust, UK; **Valeria de Angel**, BSc, MSc, Research Assistant, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London and South London and Maudsley National Health Service Foundation Trust, UK; **Fiona Patrick**, BSc, MSc, PhD Student, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; **Anthony J. Cleare**, BSc, MBBS, PhD, FRCPsych, Professor of Psychopharmacology, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London and South London and Maudsley National Health Service Foundation Trust, UK; **Allan H. Young**, MBChB, MPhil, PhD, FRCPsych, FRCP, FRSB, Professor of Mood Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London and South London and Maudsley National Health Service Foundation Trust, UK.

Correspondence: Rebecca Strawbridge, Centre for Affective Disorders, PO74 Institute of Psychiatry, Psychology and Neuroscience, King's College London, 103 Denmark Hill, London SE5 8AZ, UK. Email: becci.strawbridge@kcl.ac.uk

First received 31 May 2018, final revision 26 Sep 2018, accepted 4 Oct 2018

Supplementary material

Supplementary material is available online at <https://doi.org/10.1192/bjp.2018.233>.

Funding

This study represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley National Health Service Foundation Trust (SLaM) and King's College London. The NIHR BRC had no involvement in study design, data collection, analysis or the decision to submit for publication. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health.

References

- 1 Fekadu A, Donocik JG, Cleare AJ. Standardisation framework for the Maudsley staging method for treatment resistance in depression. *BMC Psychiatry* 2018; **18**: 100.
- 2 Fekadu A, Wooderson SC, Markopoulou K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. *J Affect Disord* 2009; **116**: 4–11.
- 3 Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. *J Clin Psychiatry* 2015; **76**: E487–98.
- 4 Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. *Int Clin Psychopharmacol* 2015; **30**: 183–92.

- 5 Strawbridge R, Carter B, Marwood L, Taylor R, Mantingh T, Nikolova V, et al. *Efficacy of Psychological and Pharmacological Augmentation Therapies for Treatment-Resistant Depression: A Systematic Review and Meta-analysis*. PROSPERO: The International Prospective Register of Systematic Reviews, 2018. Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018088009.
- 6 Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. *JAMA Psychiatry* 2017; **74**: 9–10.
- 7 National Institute for Health and Clinical Excellence (NICE). *Depression in Adults: Treatment and Management*. NICE (UK), 2017.
- 8 Scottish Intercollegiate Guidelines Network (SIGN). *Methodology Checklist 2: Controlled Trials*. 2012. Available from: <http://www.sign.ac.uk>.
- 9 Higgins J, Green S (eds). *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.
- 10 Cuijpers P, Weitz E, Cristea IA, Twisk J. Pre-post effect sizes should be avoided in meta-analyses. *Epidemiol Psychiatr Sci* 2017; **26**: 364–8.
- 11 Su T-P, Chen M-H, Li C-T, Lin W-C, Hong C-J, Gueorguieva R, et al. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. *Neuropsychopharm* 2017; **42**: 2482–92.
- 12 Fonagy P, Rost F, Carlyle J-A, McPherson S, Thomas R, Fearon RMP, et al. Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study (TADS). *World Psychiatry* 2015; **14**: 312–21.
- 13 Yoshimura R, Kishi T, Hori H, Ikenouchi-Sugita A, Katsuki A, Umene-Nakano W, et al. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2012; **39**: 355–7.
- 14 McAllister-Williams RH, Anderson IM, Finkelmeyer A, Gallagher P, Grunze HCR, Haddad PM, et al. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. *Lancet Psychiatry* 2016; **3**: 117–27.
- 15 Giralda F, Cipriani A, Agrimi E, Appino MG, Barichello A, Beneduce R, et al. Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: results and lessons of an underpowered randomised clinical trial. *BMC Res Notes* 2014; **7**: 731.
- 16 Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. *Int J Neuropsychopharmacol* 2013; **16**: 501–6.
- 17 Husain M I, Chaudhry IB, Husain N, Khoso AB, Rahman RR, Hamirani MM, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. *J Psychopharmacol (Oxf)* 2017; **31**: 1166–75.
- 18 Eisendrath SJ, Gillung E, Delucchi KL, Segal ZV, Nelson JC, McInnes LA, et al. A randomized controlled trial of mindfulness-based cognitive therapy for treatment-resistant depression. *Psychother Psychosom* 2016; **85**: 99–110.
- 19 Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. *J Clin Psychopharmacol* 2011; **31**: 638–42.
- 20 Nierenberg A, Papakostas G, Petersen T, Montoya H, Worthington J, Tedlow J, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. *J Clin Psychopharmacol* 2003; **23**: 92–5.
- 21 Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. *Prim Care Companion J Clin Psychiatry* 2008; **10**: 187–90.
- 22 Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. *J Clin Psychiatry* 2015; **76**: 1224–31.
- 23 Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. *J Clin Psychiatry* 2015; **76**: 1232–40.
- 24 Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. *J Clin Psychopharmacol* 1996; **16**: 307–14.
- 25 Hauksson P, Ingibergsdottir S, Gunnarsdottir T, Jonsdottir IH. Effectiveness of cognitive behaviour therapy for treatment-resistant depression with psychiatric comorbidity: comparison of individual versus group CBT in an interdisciplinary rehabilitation setting. *Nord J Psychiatry* 2017; **71**: 465–72.
- 26 Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. *J Clin Psychiatry*. 2007; **68**: 1071–7.
- 27 Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. *J Clin Psychiatry* 2011; **72**: 1405–12.
- 28 Bauer M, Dell'Osso L, Kasper S, Pitchot W, Vansvik ED, Koehler J, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. *J Affect Disord* 2013; **151**: 209–19.
- 29 Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2007; **68**: 843–53.
- 30 Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. *CNS Spectr* 2009; **14**: 197–206.
- 31 Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. *J Affect Disord* 1996; **41**: 201–10.
- 32 Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychopharmacol* 2008; **28**: 156–65.
- 33 Moller H-J, Demyttenaere K, Olausson B, Szamosi J, Wilson E, Hosford D, et al. Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. *World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry* 2015; **16**: 483–501.
- 34 Ozaki N, Otsubo T, Kato M, Higuchi T, Ono H, Kamijima K. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Asberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. *Psychiatry Clin Neurosci* 2015; **69**: 34–42.
- 35 Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. *Am J Psychiatry* 2001; **158**: 131–4.
- 36 Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. *Am J Psychiatry* 2006; **163**: 1519–30, quiz 1665.
- 37 Patkar AA, Masand PS, Pae C-U, Peindl K, Hooper-Wood C, Mannelli P, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. *J Clin Psychopharmacol* 2006; **26**: 653–6.
- 38 Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment-resistant unipolar depression: a randomized, open-label study. *Int Clin Psychopharmacol* 2007; **22**: 179–82.
- 39 Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet* 2018; **391**: 1357–66.
- 40 Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. *Curr Med Res Opin* 2017; **33**: 701–11.
- 41 Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. *World J Biol Psychiatry*. 2013; **14**: 334–85.
- 42 Amick HR, Gartlehner G, Gaynes BN, Forneris C, Asher GN, Morgan LC, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. *BMJ* 2015; **351**: h6019.
- 43 McPherson S, Cairns P, Carlyle J, Shapiro DA, Richardson P, Taylor D. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. *Acta Psychiatr Scand* 2005; **111**: 331–40.
- 44 Holmes EA, Ghaderi A, Harmer CJ, Ramchandani PG, Cuijpers P, Morrison AP, et al. The Lancet Psychiatry Commission on psychological treatments research in tomorrow's science. *Lancet Psychiatry* 2018; **5**: 237–86.
- 45 Wiles N, Thomas L, Abel A, Ridgway N, Turner N, Campbell J, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based

patients with treatment resistant depression: results of the CoBaIT randomised controlled trial. *Lancet* 2013; **381**: 375–84.

- 46 Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. *J Psychopharmacol Oxf Engl* 2015; **29**: 459–525.



psychiatry in history

Timothie Bright: *Melancholie, Characterie, Shakespeare and Hamlet*

Greg Wilkinson

'... stumbling in the darke midnight of ignorance ...'

Timothie Bright (1550/1–1615), Cambridge graduate and Doctor of Phisicke, published *A Treatise of Melancholie* in 1586 'from litle S. Bartlemewes by Smithfield'. Robert Burton, a melancholic Oxonian scholar and clergyman, repeatedly signals his indebtedness to Bright in his unsurpassable *The Anatomy of Melancholy*, published in 1621. Bright was a physician at St Bartholomew's Hospital from 1585 until his dismissal – for neglect of his duties – and departure on 29 September 1591. Subsequently, Bright took holy orders. He died in Shrewsbury and was probably buried there in St Mary's Church.

A Treatise of Melancholie is an early holistic English essay in psychiatry that recognises, e.g. 'the instrument of reason, the braine', 'phrensies, madnesse, lunasies, and melancholie', 'the strange effects it worketh in our minds and bodies', and integrates medicine with the religion of the era. The book was popular, with two editions in 1586 and another in 1613, and in Shakespeare's day it was the most important work on the subject. Bright addresses his (fictitious?) 'melancholicke' friend:

'Your request is not onely that I should minister unto you, what my slender skill either in divinitie or physicke may afford, but that I would at large declare unto you the nature of melancholie, what causeth it, what effects it worketh, how cured, and farther to lay open whatsoever may serve for the knowledge thereof, with such companions of feare, sadnes, desperation, teares, weeping, sobbing, sighing, as follow that mournfull traine, yea ofte times, unbridled laughter rising not from any comforte of the heart, or gladnes of spirit, but from a disposition in such sorte altered, as by error of conceite, that gesture in a counterfet manner bestowed upon that disagreeing passion, whose nature is rather to extinguish it selfe with teares, then asswaged by the sweete breath of chearfulnes, otherwise to receive refreshing.'

Characterie. An Arte of Shorte, Swifte, and Secrete Writing by Character is a form of shorthand 'invented by Timothe Bright'. *The Oxford Dictionary* indicates that Bright was the first to use the term 'characterie' (1588), the expression of thoughts by symbols or characters. Professor Dover Wilson says that characterie was much used at that time for reporting sermons of popular preachers and many have supposed the piracy of Shakespearean quartos was achieved by using it at performances. Shakespeare presumably learned the word from Bright's book, and later he used it in *The Merry Wives of Windsor* (1598).

'M.D.' writing anonymously in *Notes and Queries* in 1853 was the earliest to suggest circumstantial evidence that Shakespeare had read Bright, observing that his expression 'discourse of reason' occurs in his work. First, it is used in the 'epistle dedicatorie' of *A Treatise*:

'I haue enterlaced my treatise besides with disputes of Philosophie, that the learned sort of them, and such as are of quicke conceit, & delited in discourse of reason in naturall things, may finde to passe their time with, and know the grounds and reasons of their passions, without which they might receive more discomfort, and greater cause of error.'

Later, the phrase occurs in *Hamlet* (1603), when soliloquising on his mother's marriage ('... How weary, stale, flat, and unprofitable/Seem to me all the uses of this world'): 'O God, a beast that wants discourse of reason/Would have mourned longer-married with my uncle.'

Hamlet refers explicitly to 'my melancholy' (Act II, Scene 2) and Claudius observes: 'There's something in his soul, O'er which his melancholy sits on brood' (Act III, Scene 1). Loening's *Die Hamlet-Tragödie Shakespeares* points to Bright as the source of Shakespeare's psychology both in *Hamlet* and other plays. Loening also notes that *A Treatise* was published by Bright's publisher, Vautrollier, at his shop in Blackfriars, which is in Shakespeare's immediate neighbourhood. When Vautrollier died in 1587, his print shop and stock passed to his son-in-law, Richard Field, fellow townsman and publisher of Shakespeare's *Venus and Adonis* (1593) and *The Rape of Lucrece* (1594). O'Sullivan and Dover Wilson support the idea that Bright's *Treatise* influenced Shakespeare, and particularly *Hamlet*; they cite two score parallels not only of thought but also of phrase, indicating that Shakespeare had read *A Treatise*. Dover Wilson quotes a passage summarising most of *Hamlet's* moods (whether or not feigned):

'The perturbations of melancholy are for the most parte, sadde and fearefull, and such as rise of them: as distrust, doubt, diffidence, or dispaire, sometimes furious, and sometimes merry in appaurance, though a kinde of Sardonian, and false laughter.'

O'Sullivan also summarises Bright's references to the connection between melancholy and procrastination, which is so germane to the character of *Hamlet*.